NEW YORK (GenomeWeb News) – Molecular diagnostics company Prolias Technologies today announced it has licensed intellectual property covering microRNA-based diagnostics from Cornell University.

The technologies were developed at the Weill Cornell Medical College. The first series of IP includes a panel called Thymira that differentiates malignant from benign indeterminate thyroid nodules. Prolias, which said it anticipates commercially launching the panel in the coming months, also has licensed an algorithm to interpret results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.